Biomarker ID | 427 |
PMID | 19239456 |
Year | 2009 |
Biomarker | p53 |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | Increased Expression with Overall Death |
Odds Ratio/Hazard Ratio/Relative Risk | Univariate: HR: 2.37 (95% CI 1.84–3.05); Multivariate: HR: 1.57 (95% CI 1.21-2.05) |
Effect on Pathways | Pathways Include:- Apoptosis intrinsic pathway, Thyroid cancer,BARD1 signaling events,Fluoropyrimidine activity,Tumor suppressor Arf inhibits ribosomal biogenesis |
Experiment | Overall Survival Vs No Survival |
Type of Biomarker | Prognostic |
Cohort | The analysis included 1844 cancerous cores from 705 eligible patients with clinically localized prostate cancer, who were treated conservatively. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | Univariate: p<0.001; Multivariate: p=0.001; |
Method Used | immunohistochemistry |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | TP53 |